Resources Contact Us Home
Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers

Image Number 14 for United States Patent #5626863.

Hydrogels of polymerized and crosslinked macromers comprising hydrophilic oligomers having biodegradable monomeric or oligomeric extensions, which biodegradable extensions are terminated on free ends with end cap monomers or oligomers capable of polymerization and cross linking are described. The hydrophilic core itself may be degradable, thus combining the core and extension functions. Macromers are polymerized using free radical initiators under the influence of long wavelength ultraviolet light, visible light excitation or thermal energy. Biodegradation occurs at the linkages within the extension oligomers and results in fragments which are non-toxic and easily removed from the body. Preferred applications for the hydrogels include prevention of adhesion formation after surgical procedures, controlled release of drugs and other bioactive species, temporary protection or separation of tissue surfaces, adhering of sealing tissues together, and preventing the attachment of cells to tissue surfaces.

  Recently Added Patents
Context data in UPNP service information
Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug
Key management using quasi out of band authentication architecture
Video editing apparatus
Uni-directional transient voltage suppressor (TVS)
Hybrid CMOS nanowire mesh device and PDSOI device
  Randomly Featured Patents
Frequency folding and unfolding circuits of a video signal recording/reproducing apparatus
Cash settlement machine
Repair of a corrupt data segment used by a de-duplication engine
Extraction of water-soluble metal chelates used as catalysts in sweetening sour hydrocarbon feedstocks
Tire tread
Sports apparatus for securing the position of protective pads
Extending configuration management databases using generic datatypes
Semiconductor device, display device, and electronic device
Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
Organosilicon compounds and method for preparing same